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Background: Two-stage hepatectomy has been proposed for patients with bilateral colorectal liver
metastases. The present study assesses the feasibility and outcome of two-stage hepatectomy for the
treatment of colorectal liver metastases.
Methods: From January 1994 to December 2008, 720 patients underwent liver resections at two
institutions for colorectal liver metastases. The feasibility and outcomes of two-staged hepatectomies
were evaluated.
Results: Forty-five patients were eligible for the two-stage approach and both stages were completed
in 35 patients (78%). Reasons for failure included disease progression (n = 7), poor performance status
(n = 1) and death after the first stage (n = 2). Patients who completed both stages had significantly fewer
lesions than patients who failed to complete the second stage (5 vs. 8; P = 0.02). No differences between
the two groups were observed with regard to lesion size, receipt of radiofrequency ablation (RFA) or
presence of extrahepatic disease. Post-operative morbidity (24% vs. 26%; P = 0.9) and mortality (4% vs.
5%; P = 0.8) was similar between the first and second stages. Median overall survival was 16 months.
Three-year survival was significantly worse for patients failing to complete both stages (18%) compared
with patients completing both stages (58%) (P < 0.001). Similar survival rates were observed between
patients who completed two-stage vs. patients treated with a planned single-stage hepatectomy (58%
vs. 53%; P = 0.34).
Conclusion: The two-stage strategy for colorectal liver metastases can be performed with acceptable
morbidity and mortality. The second stage will not be feasible in 20–25% of patients.
Patients who are able to complete the two-stage approach, however, may have long-term survival
comparable to patients treated with a planned single-stage hepatectomy.
Keywords
colorectal, liver metastases, resection, two-stage, outcome
Received 11 November 2009; accepted 14 January 2010
Correspondence
Timothy M. Pawlik, Associate Professor of Surgery and Oncology, Hepatobiliary Surgery Program Direc-
tor, Department of Surgery, Harvey 611, 600 N Wolfe Street, Baltimore, MD 21287, USA. Tel: (410)
502-2387; Fax: (410) 502-2388; E-mail: tpawlik1@jhmi.edu
Introduction
Colorectal carcinoma is the second leading cause of cancer-related
deaths both in the United States and Europe,1 with more than 50%
of patients developing liver metastasis during the course of their
illness.2–4 Median survival for patients treated with chemotherapy
alone usually does not exceed 18 months. When possible, hepatic
resection is therefore the treatment of choice for patients with
colorectal liver metastasis. In fact, resection of colorectal liver
metastasis is the only potentially curative treatment option, and
has been associated with 5-year survival rates ranging from 50%
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to 58%.5–7 Unfortunately, up to 75% to 85% of patients with
colorectal metastasis are not candidates for surgical resection on
presentation.8–10 In particular, patients with multiple liver
metastases in both hemi-livers are less likely to be candidates for
surgery. Traditionally, the number of intrahepatic metastases was
considered a major adverse prognostic factor,11,12 but more
recently complete resection of multiple hepatic lesions has been
associated with a 5-year survival up to 50%.13 Improvements in
chemotherapeutic agents and surgical technique have expanded
the number of patients with multiple metastases who may be
candidates for surgical resection. However, despite the use of pre-
operative chemotherapy,14 portal vein embolization (PVE),15 and
the combination of resection and ablation,16 some patients with
bilateral, diffuse colorectal liver metastases remain ineligible for
curative resection as a result of the lack of a sufficient future liver
remnant (FLR).
In patients with multiple liver metastases in whom complete
extirpation of the metastases is not feasible by a single hepatec-
tomy, a sequential – or multiple hepatectomies – has been advo-
cated. In this approach, an initial operation removes a portion of
the metastatic disease, which is then followed by a period of time
to allow hypertrophy of the remaining liver. Then a second,
curative-intent operation is performed to extirpate all remaining
disease. Such planned staged approaches are distinguished from
unplanned repeat hepatectomies for recurrent disease.17 To date,
most data on two-stage hepatectomy have been limited. Most
series are from single institutions and have included few
patients.18–21
In the present study, we sought to examine the role of two-stage
hepatectomy in the treatment of initially unresectable patients
with diffuse liver metastases from colorectal cancer. Specifically,
we analyse not only the feasibility, but also the peri-operative and
long-term outcomes after two-stage hepatectomy. In addition, we
identify those factors associated with outcome after two-stage
hepatectomy in an international dual-centre cohort of patients.
Patients and methods
Between January 1994 and December 2008, 720 patients under-
went 853 liver resections for colorectal liver metastases at two
major hepatobiliary centres [Hepato-Biliary-Pancreatic and
Transplantation Centre (HBPTC), Curry Cabral Hospital, Lisbon,
Portugal (n = 308 patients, 372 resections) and Department of
Surgery, The Johns Hopkins University (JHU) School of Medi-
cine, Baltimore, Maryland, Unites States (n = 412 patients, 481
resections)]. The study was approved by the Institutional Review
Boards of the respective institutions. Only patients with colorectal
liver metastases who were operated on with curative intent were
included in the study. Curative intent surgery was defined as
planned complete extirpation of all known intrahepatic disease.
Patients were deemed to have disease amenable to a single curative
hepatectomy if it was anticipated that the metastases could be
completely resected, at least two adjacent liver segments could be
spared, vascular inflow and outflow could be preserved and the
volume of the liver remaining after resection would be
adequate.22,23 If these criteria were not satisfied, the patient was
considered for a two-stage hepatectomy.
Therapeutic approach
Initially in our experience we employed an operative approach
that involved initial resection of the major disease at the first
operation followed by removal of the minor disease at the second
surgery. Over time, we adopted a sequentially more aggressive
approach, in which the minor hepatectomy was performed as the
first stage followed by the major hepatectomy as the second stage.
At the discretion of the treating surgeon, portal vein ligation
(PVL) or embolization (PVE) was performed if the FLR volume
was 20% or less of the estimated total liver volume. The timing of
the second-stage procedure was determined by the adequacy of
the FLR and tumour response to chemotherapy. In the absence
of any significant tumour progression, a major hepatectomy was
later performed as the second stage. Peri-operative chemotherapy
was administered at the discretion of the treating surgeon and
medical oncologist.
Data collection
Standard demographic and clinicopathologic data were collected
on each patient such as gender, age, carcinoembryonic antigen
(CEA) level, as well as treatment-related variables including
history of chemotherapy. Data were also collected on tumour
characteristics. Specifically, data were collected on primary
tumour location, American Joint Commission on Cancer (AJCC)/
International Union against Cancer (UICC) stage (T, N, M) and
presentation (synchronous vs. metachronous). The number, size
and distribution of the hepatic metastases were noted. Resection
was classified as less than a hemihepatectomy (e.g. segmentectomy
or subsegmentectomy), hemihepatectomy or extended hepatec-
tomy (5 liver segments).24 Operative details, including the type
of resection performed and whether radiofrequency ablation
(RFA) was utilized at each stage were recorded. Peri-operative
morbidity was noted and complications were scored according to
the Clavien grading system.25 Operative mortality was defined as
death during the same hospitalization or within 90 days of
surgery. Date of last follow-up, recurrence and vital status were
recorded.
Statistical analyses
Variables of interest were compared using Student’s t-test, Pear-
son’s c2-test, or Fisher’s exact test as appropriate. Cut-off values
for continuous variables were obtained using receiver-operating
curves (ROC). Survival time was estimated using the non-
parametric product limit method (Kaplan–Meier). Differences in
survival were examined using the log-rank test. Factors associated
with recurrence and survival were examined using univariate and
multivariate analyses. A P-value less than 0.05 was considered
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significant. All statistical analyses were performed using SPSS
Version 16.0 (Chicago, IL, USA).
Results
Patient and tumour characteristics
Table 1 shows the clinicopathological features of the 45 patients in
the study. The median patient age was 58 years (range, 27–67
years) and the majority of patients were male (n = 35; 78%). Most
patients had a primary colon tumour (n = 30; 66%). The majority
of the primary tumours were advanced, with stage T3/T4 lesions
(n = 39; 86%) and had associated lymph node metastasis (n = 25;
55%). A significant portion of patients had synchronous presen-
tation of the liver metastases (n = 34; 75%). All patients had
multiple bilateral hepatic metastases. The median number of
metastases was five (range 2–13) and mean dimension of the
largest lesion was 4.0 cm (range, 1–25). Overall, 35 (78%) of
patients underwent PVL or PVE prior to the second hepatectomy.
Specifically, 32 (71%) patients underwent PVL (n = 5, PVL only vs.
n = 28, PVL plus distal injection of an alcohol sclerosant).
Extrahepatic metastases
Six (13%) patients in the series had or developed extrahepatic
disease. Three patients had extrahepatic metastases prior to the
first hepatectomy. Of these three patients, two patients had the
extrahepatic disease resected at the time of the second hepatec-
tomy. The other patient developed disease progression after the
first hepatectomy and did not complete the second hepatectomy.
Three additional patients developed extrahepatic metastases
between the first and second hepatectomies. All patients with
extrahepatic disease had received chemotherapy prior to the first
hepatectomy. Two patients received chemotherapy between the
first resection and the anticipated second hepatectomy. In total,
five patients underwent a second planned hepatectomy with
Table 1 Comparison of patients who completed and failed the two-stage approach
Variable Completed two-stage approach
(n = 35)
Failed two-stage approach
(n = 10)
P
Patient characteristics
Age (mean  SD), y 56.7  9.6 60.6  6.2 0.23
Gender, n (%)
Male 26 (74.3) 9 (90.0) 0.29
Female 9 (25.7) 1 (10.0)
Primary tumour site
Primary tumour location, n (%)
Colon 23 (65.7) 7 (70.0) 0.80
Rectum 12 (34.3) 3 (30.0)
AJCC T category, %
1/2 3.2 0.0 0.58
3/4 96.8 100.0
AJCC N category, %
0 33.3 37.5 0.83
1/2 66.7 62.5
Liver metastases
Presentation, n (%)
Synchronous 27 (77.1) 7 (70.0) 0.64
Metachronous 8 (22.9) 3 (30.0)
Number of metastases (mean) 5 8 0.02
Size of largest metastases (mean), cm 4.9 3.0 0.14
Pre-operative level of CEA (mean), ng/mL 24.4 35.6 0.71
Presence of concomitant extrahepatic disease, n (%) 2 (5.7) 1 (10.0) 0.55
Portal vein ligated or embolized, n (%) 28 (80.0) 7 (70.0) 0.66
Chemotherapy
Before first stage, n (%) 22 (62.9) 10 (10.0) 0.02
Before second stage, n (%) 24 (68.6) 4 (40.0) 0.10
After second stage, n (%) 20 (57.1) –
AJCC, American Joint Commission on Cancer; CEA, carcinoembryonic antigen.
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extrahepatic disease which was resected during the second
operation.
Feasibility
Of the 45 patients in whom a two-stage hepatectomy strategy was
planned, 35 patients actually underwent the second hepatectomy
(78%). Ten patients failed to complete the second procedure after
the first hepatectomy. Reasons for failure included disease pro-
gression (n = 7), poor performance status (n = 1) or death after the
first-stage (n = 2). Of the patients who did not undergo the
planned second stage, two were alive with disease and five were
dead as a result of disease progression at last follow-up. The
median time to death from the date of the first hepatectomy was
8 months.
Patients with a completed two-stage hepatectomy
No statistically significant differences were observed between
patients who did or did not complete the two-stage hepatectomy
in terms of age, gender or location of the primary. Compared with
those who did not complete the two-stage hepatectomy approach,
patients who succeeded had similar mean tumour size (4.9 vs.
3.0 cm, P = 0.14), rate of synchronous primaries (n = 27 vs. n = 7,
P = 0.64) and CEA levels (24.4 ng/mL vs. 35.6 ng/mL, P = 0.71).
Peri-operative chemotherapy was administrated in 32 patients
(91%), of which 22 (63%) had pre-operative chemotherapy. Of
the 27 patients who presented with synchronous liver metastases,
19 (70%) received pre-operative chemotherapy prior to a syn-
chronous resection of the primary and first hepatectomy. Overall,
24 (69%) patients had interval chemotherapy and 20 (57%) had
adjuvant chemotherapy after both operations. In 19 patients
(54%) a partial response was noted whereas in 4 (11%) a stabili-
zation occurred. On statistical analysis, the only factors associated
with an increased success of completing the second stage hepate-
ctomy were a lower mean number of metastases (5 vs. 8, P = 0.02)
and less exposure to chemotherapy prior to the first hepatectomy
(63% vs. 100%, P = 0.02).
Surgery
Seventeen patients (49%) underwent simultaneous resection of
the primary tumour at the time of the first surgery. First hepate-
ctomies were minor resections (<3 segments) in the majority of
patients (n = 34, 75%). In addition, eight (15%) patients under-
went combined resection with RFA and four (8%) patients under-
went open RFA alone. In addition to resection, ethanol ablation of
liver metastases was performed in one patient. PVL with or
without alcohol sclerosant was performed in a total of
33 (73%) patients at the time of the first operation. Two (4%)
additional patients underwent PVE after the first operation. The
majority of patients underwent the second operation within 6
months (n = 26, 58%) with a median interval between first and
second stage operations of 4.5 months (range, 2–22).
At the time of the second operation, the majority of resections
required major anatomic resections (n = 28, 80%). In addition, 6
(17%) patients also received concomitant RFA. One patient was
explored and found to have an unresectable lesion and subse-
quently underwent RFA alone. Four patients had extrahepatic
disease and underwent concomitant resections with curative
intent of lung, diaphragm or localized peritoneal disease. One
patient had extrahepatic disease involving the pancreas that was
also resected.
Surgical complications and mortality
The morbidity and mortality associated with the first and second
stage operations are summarized in Table 2. No difference was
observed in postoperative morbidity between the first and second
hepatectomies (n = 9 vs. n = 9, P = 0.9). Infectious complications
were the most common morbidity after both the first and second
procedures (n = 3 vs. n = 3). Other complications included car-
diovascular (n = 2), pulmonary (n = 2) and gastrointestinal (n =
2). Reoperation was needed in two patients in the first operation
and one patient following the second. Percutaneous drainage was
required in one patient after the first hepatectomy and four
patients after the second. There was a tendency towards more
severe complications after the second operation (Clavien grades
III and IV), with severe complications accounting for 33% of
complications after the first hepatectomy compared with 71%
after the second hepatectomy (P = 0.05).
The overall postoperative mortality rate was 8.8%. No differ-
ence was observed in postoperative mortality between the first
and second hepatectomies (n = 2; 4% vs. n = 2; 5%, P = 0.8).
Causes of mortality after the first operation were due to post-
operative hepatic insufficiency (n = 1) and pulmonary embolism
(n = 1). Post-operative hepatic insufficiency was the sole cause of
mortality after the second operation. Two of the three patients
with hepatic insufficiency had prior PVL or PVE.
Outcome
Disease recurrence was diagnosed in 62% of patient who had
successfully completed both stages. Specifically, of the 35 patients
who completed the two-stage approach, 14 patients (40%) had
died of disease, eight (23%) patients were alive with disease and 13
(37%) were disease free. Overall disease-free survival was compa-
rable between patients who completed the two-stage approach
and those who underwent a planned single-stage hepatectomy (P
= 0.44) (Fig. 1). On an intention-to-treat basis, overall 3-year
survival was 26% for all patients. The overall median survival was
16 months. Three-year survival for patients completing two-stage
hepatectomy was 58% compared with 18% for patients who failed
to complete both stages (P = 0.02) (Fig. 2). Of note, patients who
completed the two-stage approach had a similar overall survival as
patients who were able to be treated with a planned single-stage
hepatectomy (58% vs. 53%; P = 0.34) (Fig. 3).
Discussion
In the past decade, advances in chemotherapeutic efficacy and
surgical techniques have allowed surgeons to become more
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aggressive in the management of bilateral, multifocal colorectal
metastases to the liver. The two-stage hepatectomy was initially
developed as a strategy that takes advantage of the liver’s regen-
erative capabilities to allow for radical extirpation of widespread
disease. Several series in the literature have reported varying
success in selecting and successfully completing both stages of the
two-stage approach. Previous data on two-stage hepatectomy,
however, have been limited with most series being from single
institutions that included few patients.18–21 We herein report a
dual-centre international study, which is one of the largest series
to investigate the two-stage strategy for colorectal liver metastases.
We report that a two-stage strategy for colorectal liver metastases
Table 2 Comparison of operative data between the first and second stage (n = 35)
Variable First stage of
two-stage approach
Second stage of
two-stage approach
P
Type of liver-directed therapy, n (%)
Resection only 23 (65.7) 28 (80.0) 0.28
Non-resection only 4 (11.4) 1 (2.9)
Both 8 (22.9) 6 (17.1)
Type of resection, n (%)
Anatomical 9 (29.0) 24 (70.6) 0.001
Non-anatomical 8 (25.8) 1 (2.9)
Both 14 (45.2) 9 (26.5)
Major hepatectomy (3 segments), n (%) 7 (20.0) 28 (80.0) <0.001
Post-operative morbidity, n (%) 9 (25.7) 9 (25.7) 0.88
Type of Complications, n (%)
Infectious 3 (33.3) 3 (33.3)
Other 3 (33.3) 1 (11.1)
Gastrointestinal 1 (11.1) 2 (22.2)
Cardiovascular 2 (22.2) 0
Pulmonary 0 2 (22.2)
Renal 0 1 (11.1)
Single-stage approach (n=684)
Time (months)
D
is
ea
se
-f
re
e 
su
rv
iv
al
0
0.0
Patients at risk Total
35
684
30
534
24
397
16
361
1 year 2 years 3 years
0.2
0.4
0.6
0.8
1.0
12 24 36
Two-stage completed (n=35)
Two-stage completed
Single-stage approach
Figure 1 Overall disease-free survival was comparable between patients who completed the two-stage approach and those who underwent
a planned single-stage hepatectomy
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can be performed safely with acceptable morbidity and mortality.
Importantly, the second stage was not feasible in 20–25% of
patients in whom it was initially planned. However, for those
patients who were able to complete the two-stage approach, long-
term survival was possible and was comparable with patients
treated with a planned single-stage hepatectomy.
The feasibility of being able to complete both stages of the
two-stage approach has always been of some concern. Several
small series had previously reported that the second stage was only
feasible in 60–81% of patients with bilateral multifocal colorectal
liver metastases.18–21,26 Historically, resection of patients with mul-
tiple lesions – especially those with four or more lesions – was
Two-stage completed (n=35)
Time (months)
P
ro
p
o
rt
io
n
 s
u
rv
iv
in
g
0
0.0
Patients at risk Total
35
10
31
2
26
2
20
2
1 year 2 years 3 years
0.2
0.4
0.6
0.8
1.0
12 24 36
Two-stage failed (n=10)
Two-stage completed
Two-stage failed
Figure 2 Three-year survival for patients completing a two-stage hepatectomy was 58% compared with only 18% for patients who failed to
complete both stages
Two-stage completed (n=35)
Time (months)
P
ro
p
o
rt
io
n
 s
u
rv
iv
in
g
0
0.0
Patients at risk Total
35
684
31
595
26
472
20
363
1 year 2 years 3 years
0.2
0.4
0.6
0.8
1.0
12 24 36
Single-stage approach (n=684)
Two-stage completed
Single-stage approach
Figure 3 Patients who completed the two-stage approach had a similar overall survival as patients who were able to be treated with a
planned single-stage hepatectomy
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controversial with reported poor disease-free and overall survival
for this group of patients.11,12 More recently, in the era of more
effective cytotoxic chemotherapy, Pawlik et al. has reported a
5-year survival of over 50% for patients with four or more
metastases treated with hepatic resection and systemic chemo-
therapy.13 In addition, a recent meta-analysis examining the out-
comes of patients with more than four colorectal liver metastases
demonstrated a benefit of resection.26 Given the improvement in
overall survival after hepatic resection in patients with larger
burdens of intrahepatic disease, as well as the improved morbidity
and mortality rates associated with hepatectomy, some have advo-
cated for a more expanded criteria of resectability for colorectal
liver metastasis.22 Specifically, if all disease within the liver can be
removed while leaving an adequate FLR then resection may be
considered. As such, the two-stage approach may help expand the
pool of potentially resectable patients to include those with mul-
tiple bilateral hepatic metastases who otherwise would not be
considered candidates for complete surgical extirpation of all
metastatic disease.
We noted that patients who failed to complete the two-stage
approach were more likely to have received chemotherapy prior to
the first resection. To some degree, receipt of chemotherapy was
likely a surrogate for a perceived more aggressive initial clinical
presentation. Perhaps, more importantly, was the fact that of the
10 patients who failed to undergo the second stage, seven patients
had progressive disease on chemotherapy. In contrast, most
patients who completed the two-stage approach demonstrated
stable disease or a partial response to chemotherapy. Wichert et al.
similarly reported that patients who failed to complete the two-
stage approach were more likely to have experienced multiple lines
of chemotherapy.27 Tumour progression while receiving systemic
chemotherapy has been shown to be a powerful poor prognostic
indicator in patients with initially resectable metastases.28,29
Patients being considered for a two-stage hepatectomy probably
represent a cohort of patients with even more advanced disease,
and the relationship between chemotherapeutic responsiveness
and outcome needs to be strongly considered when managing
these patients.
The potential surgical morbidity in managing patients with
multiple bilateral colorectal metastases has also been an area of
ongoing concern. The two-stage approach involves the resection
of a considerable amount of hepatic parenchyma and therefore
may increase the risk of postoperative hepatic insufficiency. Initial
experiences with the two-stage approach that did not incorporate
PVL or PVE were associated with a high incidence of hepatic
insufficiency and high mortality rates (9–15%).21,30 More recently,
the addition of PVL or PVE has been incorporated into the two-
stage strategy and has resulted in a reduction in the incidence of
postoperative hepatic insufficiency and death.18–20,27 In our series,
the majority of patients initially lacked a sufficient FLR and 78%
of patients underwent either a PVL at the time of the first opera-
tion or PVE between the first and second stages. In addition to the
volume of the FLR, underlying hepatic parenchymal injury may
also contribute to risk of post-operative liver dysfunction. This is
particularly important in patients being considered for a two-
stage approach, as these patients all have extensive disease and
have often received extensive preoperative chemotherapy. Pre-
vious studies have noted that prolonged courses of oxaliplatin and
irinotecan-based chemotherapies were associated with hepatic
injury and perhaps an increase in peri-operative mortality.31,32 In
one series of two-stage hepatectomy patients, up to 64% were
found to have macrosteatosis or steatofibrosis by liver biopsy at
the time of the first-stage hepatectomy.18 As such, coordination
between the medical oncologist and hepatobiliary surgeon is vital,
to optimize the duration of chemotherapy so as to minimize the
risk of prolonged chemotherapy.
Although early reports of survival after two-stage hepatectomy
were initially modest, more recent series have reported 3-year
overall survival rates ranging from 54% to 60% and a single series
has reported a 5-year survival rate of 42%.18,27,33 Similarly, we
observed a 3-year survival rate of 58% for patients completing the
two-stage approach. Importantly, despite an initial presentation
with bilateral, multifocal liver metastases, patients in the current
series who successfully completed the two-stage approach had an
overall survival that was comparable to patients who underwent a
planned single-staged hepatectomy. These data strongly suggest
that even in the setting of extensive metastatic disease, appropri-
ately selected patients may derive a substantial survival benefit
from two-stage hepatectomy when such an approach is performed
with curative intent and complete extirpation of all disease. Our
data similarly show that the two-stage approach can be done with
reasonable safety that is comparable to population-based esti-
mates of peri-operative morbidity and mortality for other hepa-
tectomy patients.33,34 A multidisciplinary approach is paramount,
however, in the selection and management of patients being con-
sidered for the two-stage approach in order to maximize the
therapeutic options and clinical outcomes.
Conclusion
For patients with bilateral multifocal colorectal liver metastases, a
two-stage approach can be performed with acceptable morbidity
and mortality. The addition of PVE or PVL can decrease the
incidence of postoperative hepatic insufficiency. With careful
patient selection and management, patients managed with a two-
stage approach can achieve long-term survival that is comparable
to patients treated with a planned single-stage hepatectomy.
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